Company / Return on Equity (ROE)
Spero Therapeutics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-148.7%
FY2025
5-year range
-148.7% / 21.3%
FY2021-FY2025
Trend
-796.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Spero Therapeutics, Inc. reports negative total equity of -148.7% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-148.7% in FY2025 with a 5-year CAGR of -67.0%.
Declined from -61.1% to -148.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -47.0pp
- 5-Year Change
- -67.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 796.6% year-over-year.
- Peak return on equity (roe) was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -148.7% | -796.6% |
| FY2024 | 21.3% | +134.9% |
| FY2023 | -61.1% | +39.9% |
| FY2022 | -101.7% | -71.4% |
| FY2021 | -59.3% | +27.4% |
| FY2020 | -81.7% | -46.0% |
| FY2019 | -55.9% | -153.4% |
| FY2018 | -22.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026